- •This population-based survey of 5004 French women confirms the high frequency of climacteric symptoms as well as of genitourinary syndrome of menopause (GSM) in the first 15 years of menopause.
- •The impact of climacteric/GSM symptoms on quality of life appeared significant, with 25 % of the women aged 55–59 years rating their quality of life between 8 and 10 on a 10-point visual analogic scale.
- •About 44 % of the surveyed women never discussed their climacteric/GSM symptoms with their health care provider.
- •Only, 6 % of the women were taking menopause hormone treatment (MHT) at the time of the survey.
- •The main reasons for not using MHT were fear of hormones and of MHT side-effects.
- •62 % of the women reported that the decision not to take MHT was supported by their physician.
Design, setting, and participants
Main outcomes and measures
Conclusions and relevance
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of Women's Health Across the Nation.Am. J. Public Health. 2006; 96: 1226-1235https://doi.org/10.2105/AJPH.2005.066936
- Duration of menopausal vasomotor symptoms over the menopause transition.JAMA Intern. Med. 2015; 175: 531https://doi.org/10.1001/jamainternmed.2014.8063
- Duration of menopausal hot flushes and associated risk factors.Obstet. Gynecol. 2011; 117: 1095-1104https://doi.org/10.1097/AOG.0b013e318214f0de
- Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort.Menopause. 2014; 21: 924-932https://doi.org/10.1097/GME.0000000000000196
- Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups.Soc. Sci. Med. 2001; 52: 345-356https://doi.org/10.1016/S0277-9536(00)00147-7
- Age of menopause and impact of climacteric symptoms by geographical region.Climacteric. 2010; 13: 419-428https://doi.org/10.3109/13697137.2010.507886
- Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden.Menopause. 2021; 28: 875-882https://doi.org/10.1097/GME.0000000000001793
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s health initiative randomized controlled trial.JAMA J. Am. Med. Assoc. 2002; 288: 321-333https://doi.org/10.1001/jama.288.3.321
- A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative.Menopause. 2012; 19: 616-621https://doi.org/10.1097/gme.0b013e31824bb039
- Evolution of postmenopausal hormone therapy between 2002 and 2009.Menopause. 2012; 19: 610-615https://doi.org/10.1097/gme.0b013e31823a3e5d
- Postmenopausal hormone therapy initiation before and after the Women’s health initiative in two French cohorts.Menopause. 2011; 18: 219-223https://doi.org/10.1097/gme.0b013e3181ecf3ec
- Menopausal hormone therapy use in 17 European countries during the last decade.Maturitas. 2014; 79: 287-291https://doi.org/10.1016/j.maturitas.2014.07.002
- Estimated numbers of postmenopausal women treated by hormone therapy in France.Maturitas. 2005; 52: 296-305https://doi.org/10.1016/j.maturitas.2005.05.002
- IMS recommendations on women's midlife health and menopause hormone therapy.Climacteric. 2016; 19: 109-150https://doi.org/10.3109/13697137.2015.1129166
- Revised global consensus statement on menopausal hormone therapy.Maturitas. 2016; 91: 153-155https://doi.org/10.1016/j.maturitas.2016.06.001
- BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.Post Reprod. Health. 2021; 27: 49-55https://doi.org/10.1177/2053369120983154
- Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d’Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines.Maturitas. 2022; 163: 62-81https://doi.org/10.1016/j.maturitas.2022.05.008
- The 2022 hormone therapy position statement of The North American Menopause Society.Menopause. 2022; 29: 767-794https://doi.org/10.1097/GME.0000000000002028
- Health-related quality of life in a multiethnic sample of middle-aged women: study of Women's Health Across the Nation (SWAN).Med. Care. 2003; 41: 1262-1276https://doi.org/10.1097/01.MLR.0000093479.39115.AF
- Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes.Menopause. 2009; 16: 286-292https://doi.org/10.1097/gme.0b013e31818c0485
- Severe hot flashes are associated with chronic insomnia.Arch. Intern. Med. 2006; 166: 1262https://doi.org/10.1001/archinte.166.12.1262
- A multinational study of sleep disorders during female mid-life.Maturitas. 2012; 72: 359-366https://doi.org/10.1016/j.maturitas.2012.05.011
- Associations between menopausal hormone therapy and sleep disturbance in women during the menopausal transition and post-menopause: data from the Norwegian prescription database and the HUNT study.BMC Womens Health. 2020; 20: 64https://doi.org/10.1186/s12905-020-00916-8
- Hot flashes, insomnia, and the reproductive stages: a cross-sectional observation of women from the EPISONO study.J. Clin. Sleep Med. 2021; 17: 2257-2267https://doi.org/10.5664/jcsm.9432
- Genitourinary syndrome of menopause: a systematic review on prevalence and treatment.Menopause. 2021; 28: 706-716https://doi.org/10.1097/GME.0000000000001752
- Factors associated with developing vaginal dryness symptoms in women transitioning through menopause: a longitudinal study.Menopause. 2018; 25: 1094-1104https://doi.org/10.1097/GME.0000000000001130
- Meanings of menopause: cultural influences on perception and management of menopause.J. Holist. Nurs. 2007; 25: 106-118https://doi.org/10.1177/0898010107299432
- The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women.Post Reprod. Health. 2020; 26: 181-209https://doi.org/10.1177/2053369120957514
- Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative Randomized Trials.JAMA. 2017; 318: 927https://doi.org/10.1001/jama.2017.11217
- Menopause management — getting clinical care back on track.N. Engl. J. Med. 2016; 374: 803-806https://doi.org/10.1056/NEJMp1514242
- Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results.Menopause. 2019; 26: 588-597https://doi.org/10.1097/GME.0000000000001282
- Prescribing of menopausal hormone therapy in Germany: current status and changes between 2004 and 2016.Pharmacoepidemiol. Drug Saf. 2021; 30: 462-471https://doi.org/10.1002/pds.5186
- Prevalence of the use of oral contraceptives and hormone replacement therapy in Japan: the Japan Nurses' Health Study.J. Epidemiol. 2022; 32: 117-124https://doi.org/10.2188/jea.JE20200207
- Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicine call centre.BMC Womens Health. 2021; 21: 348https://doi.org/10.1186/s12905-021-01478-z
- Shock, terror and controversy: how the media reacted to the Women's Health Initiative.Climacteric. 2012; 15: 275-280https://doi.org/10.3109/13697137.2012.660048
- Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial.JAMA. 2004; 291: 1701https://doi.org/10.1001/jama.291.14.1701
- Menopause preparedness: perspectives for patient, provider, and policymaker consideration.Menopause. 2021; 28: 1186-1191https://doi.org/10.1097/GME.0000000000001819